



Forward Texas: TAMEST Conversations on COVID-19 Treatment and Vaccine Development

Maria Elena Bottazzi PhD FASTMH

Associate Dean and Professor

Co-Section Head, Pediatric Tropical Medicine

Co-Director, Texas Children's Center for Vaccine Development

Baylor
College of
Medicine

NATIONAL SCHOOL OF
TROPICAL
MEDICINE



Texas Children's
Hospital®

Leading the development and testing of low-cost and effective vaccines against emerging and neglected tropical diseases

FASTERCURES

COVID-19 Treatment and Vaccine Tracker



Many platforms are not currently the basis for licensed vaccines

For some platforms, adjuvants are proprietary

Public information on the specific SARS-CoV-2 antigen(s) used is limited

Need several to suited to specific population subtypes


- elderly
- children
- pregnant women or
- immunocompromised patients



Current Count of Treatments and Vaccines

223 treatments
in consideration

141 vaccines
in development



The US Approach

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

Goal: A harmonized and collaborative approach for

- clinical testing (Phase 3 onwards)
- scale-up
- distribution

More than one effective vaccine (drug) approach likely will be required

Studies conducted in parallel to generate essential safety and efficacy data and accelerate the licensure and distribution

NIH to facilitate collaborations with discussions on trial designs and data sharing between government, academics industry, and funders



Operation Warp Speed announces finalists of its funding initiative

By GlobalData Healthcare

SHARE

The five vaccines include Moderna's mRNA1273, currently in phase 2 trials; AstraZeneca and Oxford University's AZD1222, now in clinical trials at multiple UK sites; a candidate from Johnson & Johnson; a Merck vaccine based on that company's successful Ebola vaccine; and Pfizer and BioNTech's BNT162.



Now, five finalists for funding have been chosen - AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer.
Credit: joel bubble ben / Shutterstock.

Finance

Health



Navigate 1 of COVID-19 tech, med & telecom

Academy

The Rest of the World - A Commitment to Global Access

ACT Accelerator

Equitable global access to innovative tools for COVID-19 for all
Unprecedented level of partnership

Create a strong unified voice to maximize impact

Build on past experiences towards achieving this objective

Accountable to the world, to communities, and to one another.

Baylor
College of
Medicine

Texas Children's
Hospital

ACCESS TO COVID-19 TOOLS (ACT) ACCELERATOR

A Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines

24 April 2020

COMMITMENT and CALL TO ACTION

Our Vision and Mission

Grounded in a vision of a planet protected from human suffering and the devastating social and economic consequences of COVID-19, we, an initial group of global health actors (BMGF, CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust, WHO) and private sector partners and other stakeholders, are launching

Our Mission is not only accelerated development and availability of new COVID-19 tools – it is to accelerate equitable global access to safe, quality, effective, and affordable COVID-19 diagnostics, therapeutics and vaccines, and thus to ensure that in the fight against COVID-19, no one is left behind.

BILL & MELINDA
GATES foundation

CEPI

dcvnm
Developing Countries Vaccine
Manufacturers Network

Gavi
The Vaccine Alliance

TheGlobalFund

IFPMA
International Federation
of Pharmaceutical
Manufacturers & Associations

IGBA
INTERNATIONAL GENETIC AND
BIOMEDICAL ASSOCIATION

Unitaid
Innovation in Global Health

W
wellcome

World Health
Organization

Aligning to Achieve Global Access



TRUSTED
COLLABORATIONS



STRICT
COMPLIANCE

SARS CoV RBD
RBD219-N1

- cGMP Manufactured in 2016
- "Shovel ready" start of phase 1 clinical trial Q3 2020
- Investigational vaccine recommended for outbreak use in 2021

SARS CoV2 RBD

- cGMP manufacture targeted for Q3 2020
- Start of phase 1 clinical trial 2021
- Investigational vaccine recommended for outbreak use in 2022, possibly earlier

dcvmn

Developing Countries Vaccine
Manufacturers Network

